1 / 50

INTRODUCTION to PHARMACOLOGY

INTRODUCTION to PHARMACOLOGY. MEDICINE IN ANCIENT EGYPT. EARLY MESOPOTAMIAN CULTURE. PRIMITIVE AMERICAN INDIAN CULTURES. HIPPOCRATES: MEDICINE BECAME A SCIENCE. TERMS to REMEMBER. DRUG PHARMACOLOGY CLINICAL PHARMACOLOGY pharmacokinetics pharmacodynamics PHARMACOTHERAPEUTICS.

elin
Download Presentation

INTRODUCTION to PHARMACOLOGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. INTRODUCTION toPHARMACOLOGY

  2. MEDICINE IN ANCIENT EGYPT

  3. EARLY MESOPOTAMIAN CULTURE PRIMITIVE AMERICAN INDIAN CULTURES

  4. HIPPOCRATES: MEDICINE BECAME A SCIENCE

  5. TERMS to REMEMBER • DRUG • PHARMACOLOGY • CLINICAL PHARMACOLOGY • pharmacokinetics • pharmacodynamics • PHARMACOTHERAPEUTICS

  6. PROPERTIES OF IDEAL DRUG • EFFECTIVENESS (EFFICACY) • SAFETY • SELECTIVITY • REVERSIBILITY • PREDICTABILITY • EASE OF ADMINISTRATION • LACK OF DRUG INTERACTIONS • LOW COST • Chemical stability • SIMPLE NAME

  7. NO DRUG IS IDEAL

  8. FACTORS THAT DETERMINEINTENSITY OF DRUG RESPONSES

  9. INDIVIDUAL VARIATION Ch.8 • AGE • GENDER • WEIGHT • KIDNEYS • LIVER • GENETIC

  10. NURSE’S ROLE(patient care) • PREADMINISTRATION ASSESSMENT • DOSAGE & ADMINISTRATION • EVALUATING & PROMOTING THERAPEUTIC EFFECTS • MINIMIZING ADVERSE EFFECTS • MINIMIZING ADVERSE INTERACTIONS • MAKING PRN DECISIONS • MANAGING TOXCITY

  11. NURSE’S ROLE(patient education) • DRUG NAME & THERAPEUTIC CATEGORY • DOSAGE • SCHEDULE • ROUTE OF ADMIN • EXPECTED RESPONSE • MEASURES TO ENHANCE RESPONSE • DURATION OF TX • METHOD OF STORAGE • INTERACTIONS • WHO TO CALL

  12. NURSING PROCESS • ASSESSMENT • ANALYSIS (nursing diagnosis) • PLANNING • IMPLEMENTATION • EVALUATION

  13. LEGISLATION • 1906 – Pure Food and Drug Act • free of adulterants (nothing @safety or effectiveness) • 1938 – Food Drug and Cosmetic Act • 1st to regulate safety • 1962 – Harris- Kefauver Amendments • proof of effectiveness • 1970 – Controlled Substances Act • regulates drugs with potential for abuse • 1992 – accelerated approval • 1997 – FDA Modernization Act • 2002 – BEST PHARMACEUTICALS FOR CHILDREN ACT • 2003 – PEDIATRIC RESEARCH EQUITY ACT

  14. DRUG DEVELOPMENT • PRECINICAL TESTING – 1-5 yrs • evaluation of drug prior to testing in humans (toxicities, pharmacokinetics, useful biological effects) • CLINICAL TRIALS – 2-10 yrs • Phase 1 – nl volunteers • Phase II and III - patients to determine safety, effectiveness and dose ranges • Phase IV- post market surveillance

  15. DRUG NAMES

  16. EXAMPLES OF LOOK-ALIKE TRADE-NAMES

  17. EXAMPLES of SOUND-ALIKE TRADE NAMES

  18. WHAT DOES the BODY DO to the DRUG??

  19. PHARMACOKINETICS • ABSORPTION • DISTRIBUTION • METABOLISM • EXCRETION

  20. DISSOLUTION

  21. TYPES OF ABSORPTION • PASSIVE ABSORPTION • ACTIVE ABSORPTION • PINOCYTOSIS

  22. FACTORS THAT AFFECTABSORPTION • BLOOD FLOW • PAIN • STRESS • HUNGER • FASTING • FOOD • ph • EXERCISE • ROUTE OF ADMINISTRATION

  23. FIRST PASS EFFECT BIOAVAILABILITY

  24. FACTORS THAT AFFECTDISTRIBUTION • PROTEIN BINDING • BLOOD FLOW • BODY TISSUE AFFINITY

  25. HALF-LIFE 4 – 8 HRS  SHORT HALF-LIFE 24 HRS LONG HALF-LIFE THE TIME IT TAKES FOR HALF OF THE DRUG CONCENTRATION TO BE ELIMINATED STEADY STATEdrug intake = amount excreted…… therefore!!...........serum conc. = therapeutic effect

  26. FACTORS THAT AFFECTEXCRETION • RENAL FUNCTION ( GFR, Cr Cl) • LIVER FUNCTION • BILE, FECES, LUNGS, SALIVA, SWEAT, BREAST MILK • URINE ph • DOSAGE

  27. WHAT DOES the DRUG DO to the BODY??

  28. PHARMOCODYNAMICS • DOSE RESPONSE/MAXIMAL EFFICACY • ONSET, PEAK, DURATION OF ACTION • RECEPTOR THEORY • AGONIST/ANTAGONIST (STIMULATOR/INHIBITOR-BLOCKER ;MIMETIC/LYTIC) • SPECIFIC- NON/SELECTIVE-NON (moa) • CATEGORIES OF DRUG ACTION • STIMULATORS/DEPRESSOR,,REPLACEMENT, INHIBITION/KILLING/IRRITATION • THERAPEUTIC INDEX/RANGE • PEAK AND TROUGH • LOADING DOSE • SIDE EFFECTS • PHARMACOGENETICS • TACHYPHYLAXIS (TOLERANCE) • PLACEBO EFFECT (PSYCHOLOGIC BENEFIT)

  29. Oral vaccine could help epilepsy and stroke patients By Emma Reid, February 25, 2000People who suffer from epilepsy, stroke or other brain traumas often have very high levels of brain activity during an episode or an attack. This high level of activity can cause an unpleasant chain of events leading to brain cell death. Researchers from the Jefferson Medical College in Philadelphia, PA have developed a way to reduce the 'high activity' response in rats using an important oral vaccine. The oral vaccine stimulates the production of antibodies which block an important receptor in the brain , preventing glutamate from binding to receptor sites (like on the lower cell in the image and sending messages along the chain.

  30. Always remember to check the name (trade and generic), dosage form, strength, and indication (reason the drug is being prescribed) before giving it to a patient. An error may have been made before you received the order! A complete list of more than 800 sound-alike trade names can be found on the United States Pharmacopeia (USP).

  31. John G is receiving an experimental drug (AK22) for the treatment of actinic keratosis, a skin lesion that, if untreated, will progress to a skin cancer called squamous cell carcinoma. The drug is delivered in a cream applied to the lesions twice a day.

  32. After 3 weeks, John’s lesions have fewer scales and are less red. Some have disappeared. The science of what AK22 does tothe body is called: • pharmacokinetics. • pharmacognosy. • pharmacodynamics. • toxicology.

  33. DRUG INTERACTIONS PHARMACOKINETIC PHARMOCODYNAMIC

More Related